Regent Pacific Group's (HKG:0575) commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group, has submitted a new drug application (NDA) for Senstend to China's National Medical Products Administration, a Wednesday bourse filing said.
Senstend is a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for the treatment of premature ejaculation.
Jiangsu Wanbang Biopharmaceutical Group is a wholly-controlled company of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196).
Price (HKD): $0.33, Change: $-0.015, Percent Change: -4.35%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。